Table 2.
Clinical characteristics and profile of administered anti-Parkinsonian drugs.
| N | Gender | Age | Weight (kg) | Height (cm) | BMI | PD years | HY | Mini-Cog | Medication (mg/day) | LEDD (mg) |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 70 | 76 | 160 | 29.7 (ow) | 12 | 3 | 5 | LD (750) PR(2.1) RA (1) | 1110 |
| 2 | M | 63 | 75 | 160 | 29.3 (ow) | 4 | 2 | 5 | LD (600) RA (1) | 700 |
| 3 | M | 70 | 63 | 167 | 22.6 | 6 | 2 | 5 | LD (750) PR (0.18) RA (1) | 868 |
| 4 | F | 68 | 68 | 168 | 24.4 | 11 | 2.5 | 5 | LD (800) RA (1) RO (4) | 980 |
| 5 | F | 58 | 67 | 167 | 24 | 11 | 2 | 5 | LD (800) PR (1.06) | 906 |
| 6 | M | 66 | 69 | 166 | 23.1 | 3 | 2.5 | 5 | LD (475) RO (24) | 955 |
| 7 | M | 66 | 65 | 172 | 22 | 6 | 2.5 | 5 | LD (600) RA (1) RO (4) | 555 |
| 8 | M | 70 | 70 | 165 | 25.7 (ow) | 12 | 2.5 | 5 | LD (600) PR (2.1) RA (1) | 910 |
| 9 | F | 59 | 90 | 173 | 30.1 (mo, cl-1) | 8 | 2 | 5 | LD (600) PR (2.1) RA (1) | 910 |
| 10 | M | 70 | 81 | 180 | 25 (ow) | 9 | 2.5 | 5 | LD (600) PR(0.52) RA(1) AM (100) | 852 |
| 11 | M | 54 | 68 | 167 | 24.4 | 7 | 2.5 | 5 | RA (1) RO (16) | 420 |
| 12 | F | 70 | 68 | 160 | 26.6 (ow) | 2 | 1.5 | 5 | PR (0.52) | 52 |
| 13 | M | 69 | 75 | 170 | 26.0 (ow) | 5 | 2 | 5 | LD (200) RA (1) RO (8) | 460 |
| 14 | F | 67 | 75 | 152 | 25.4 (ow) | 10 | 2.5 | 5 | LD (800) PR (0.26) RA (1) AM (200) | 1126 |
| 15 | M | 67 | 81 | 169 | 25.4 (ow) | 3 | 2 | 5 | LD (500) PR (1.58) | 658 |
| 16 | M | 64 | 94 | 190 | 26.0 (ow) | 3 | 2.5 | 5 | LD (800) PR (0.52) | 852 |
| 17 | M | 70 | 92 | 172 | 31.1 (mo, cl-1) | 12 | 2.5 | 5 | LD (800) RA (1) | 900 |
| Average | 65.9 ± 4.87 years | 75.1 (±9.6) kg | 168.2 (±8.5) cm | 25.92 (±2.6) | 7.3 ± 3.6 years | 2.3 ± 0.35 | 5 | — | 777 (±275) mg | |
| Limits | 54–70 years | 65–92 kg | 152–190 cm | 22–31.1 | 3–12 years | 1.5–3 | — | 52–1126 mg |
HY = Hoehn and Yahr stage; AM = amantadine; LD = levodopa; PR = pramipexole; RA = rasagiline; RO = ropinirole; LEDD = L-dopa equivalent daily dose (mg/day); ow = overweight; mo, cl 1 = moderate obesity, class I.